CO6821949A2 - Composiciones estables de povidona yodada con esteroides con antiinflamatorios no esteroidales - Google Patents

Composiciones estables de povidona yodada con esteroides con antiinflamatorios no esteroidales

Info

Publication number
CO6821949A2
CO6821949A2 CO13287528A CO13287528A CO6821949A2 CO 6821949 A2 CO6821949 A2 CO 6821949A2 CO 13287528 A CO13287528 A CO 13287528A CO 13287528 A CO13287528 A CO 13287528A CO 6821949 A2 CO6821949 A2 CO 6821949A2
Authority
CO
Colombia
Prior art keywords
inflammatories
steroids
steroidal anti
povidone iodine
stable compositions
Prior art date
Application number
CO13287528A
Other languages
English (en)
Spanish (es)
Inventor
Jason Stein
Michael Weiser
Joseph A Capriotti
Bo Liang
Michael Samson
Original Assignee
Foresight Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47139697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6821949(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Foresight Biotherapeutics Inc filed Critical Foresight Biotherapeutics Inc
Publication of CO6821949A2 publication Critical patent/CO6821949A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO13287528A 2011-05-12 2013-12-09 Composiciones estables de povidona yodada con esteroides con antiinflamatorios no esteroidales CO6821949A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161485475P 2011-05-12 2011-05-12

Publications (1)

Publication Number Publication Date
CO6821949A2 true CO6821949A2 (es) 2013-12-31

Family

ID=47139697

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13287528A CO6821949A2 (es) 2011-05-12 2013-12-09 Composiciones estables de povidona yodada con esteroides con antiinflamatorios no esteroidales

Country Status (16)

Country Link
US (1) US20150038473A1 (OSRAM)
EP (1) EP2707006B1 (OSRAM)
JP (2) JP6072009B2 (OSRAM)
KR (1) KR101967938B1 (OSRAM)
CN (1) CN103957922A (OSRAM)
AR (1) AR086399A1 (OSRAM)
AU (3) AU2012253335B2 (OSRAM)
BR (1) BR112013028735A2 (OSRAM)
CA (1) CA2835343A1 (OSRAM)
CL (1) CL2013003016A1 (OSRAM)
CO (1) CO6821949A2 (OSRAM)
EC (1) ECSP13013069A (OSRAM)
MX (1) MX360666B (OSRAM)
PE (1) PE20141070A1 (OSRAM)
TW (2) TWI632914B (OSRAM)
WO (1) WO2012155062A1 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2665195B2 (ja) 1995-05-19 1997-10-22 日本電気移動通信株式会社 Ｍｃａシステムにおける移動局の個別番号表示方法
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TW201325601A (zh) * 2011-09-16 2013-07-01 Foresight Biotherapeutics Inc 安定之普維酮－碘組成物
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
HK1208162A1 (en) 2012-05-03 2016-02-26 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US20150366879A1 (en) * 2013-02-15 2015-12-24 Senju Pharmaceutical Co., Ltd. Difluprednate emulsion composition containing antimicrobial metal
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3062618B1 (en) 2013-11-01 2020-02-05 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
BR112018016398A2 (pt) 2016-02-18 2018-12-18 Invirsa Inc métodos para o uso de 5'-adenosina difosfato ribose (adpr)
MX385752B (es) 2016-04-14 2025-03-18 Azura Ophthalmics Ltd Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfunción de las glándulas de meibomio.
MX2018013507A (es) * 2016-05-05 2019-09-11 Veloce Biopharma Llc Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo.
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR101935250B1 (ko) * 2017-07-04 2019-01-04 김대황 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물
JP7242696B2 (ja) 2018-03-27 2023-03-20 インバーサ， インコーポレイテッド ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明
CN113797163B (zh) * 2020-06-17 2023-07-14 成都瑞沐生物医药科技有限公司 一种滴眼给药防治干性黄斑病变和视网膜光损伤的眼用制剂
CN112305115B (zh) * 2020-10-29 2022-08-23 诺峰药业(成都)有限公司 一种检测二氟泼尼酯眼用乳剂中的降解杂质及其含量的高效液相色谱方法
KR20220062790A (ko) 2020-11-09 2022-05-17 정춘영 포비돈 아이오딘계 소독액
CA3203779A1 (en) * 2021-01-21 2022-07-28 Joon Youb Lee Ophthalmic composition
US20250281395A1 (en) * 2021-01-22 2025-09-11 Chengdu Ruimu Biopharmaceuticals Co., Ltd. Ophthalmic preparation for treating macular edema, optic neuritis and non-infectious endophthalmitis through eye drop administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886268A (en) * 1972-05-30 1975-05-27 Synergistics Iodophor-steroid compound pharmaceutical compositions
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
PT2291081T (pt) * 2008-06-12 2020-09-10 Takeda Pharmaceuticals Co Iodopovidona, um novo conservante alternativo para composições oftálmicas
WO2011084473A1 (en) * 2009-12-15 2011-07-14 Foresight Biotherapeutics, Inc. Non-irritating ophthalmic povidone-iodine compositions
TW201325601A (zh) * 2011-09-16 2013-07-01 Foresight Biotherapeutics Inc 安定之普維酮－碘組成物

Also Published As

Publication number Publication date
EP2707006A4 (en) 2014-09-24
AR086399A1 (es) 2013-12-11
PE20141070A1 (es) 2014-09-14
AU2012253335A1 (en) 2013-05-02
KR20140045375A (ko) 2014-04-16
JP2017095474A (ja) 2017-06-01
AU2018203492A1 (en) 2018-06-07
JP6359619B2 (ja) 2018-07-18
TW201311256A (zh) 2013-03-16
MX360666B (es) 2018-11-13
EP2707006A1 (en) 2014-03-19
TW201811340A (zh) 2018-04-01
TWI632914B (zh) 2018-08-21
JP2014516954A (ja) 2014-07-17
KR101967938B1 (ko) 2019-04-10
AU2016222491A1 (en) 2016-09-22
BR112013028735A2 (pt) 2017-12-05
CL2013003016A1 (es) 2014-05-02
CN103957922A (zh) 2014-07-30
EP2707006B1 (en) 2019-07-03
JP6072009B2 (ja) 2017-02-01
AU2012253335B2 (en) 2016-08-04
WO2012155062A1 (en) 2012-11-15
ECSP13013069A (es) 2015-03-31
TWI717552B (zh) 2021-02-01
CA2835343A1 (en) 2012-11-15
MX2013012971A (es) 2013-12-12
US20150038473A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
CO6821949A2 (es) Composiciones estables de povidona yodada con esteroides con antiinflamatorios no esteroidales
SMT201600308B (it) Composti di benzene arile-o eteroarile-sostituiti
DK3235812T3 (da) Deutererede derivater af ivacaftor
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
EP2713762A4 (en) Stevia-COMPOSITION
EP2736491A4 (en) BEPOTASTIN COMPOSITION
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
EP2758441A4 (en) MODIFIED POLYETHYLENE COMPOSITIONS
DK3456831T3 (da) Målrettet modifikation af rottegenom
CO7061086A2 (es) Combinaciones de compuestos activos
LT2791160T (lt) Modifikuotos mrnr sudėtys
DK2854514T3 (da) Udvalg af symbiota ved screening af multiple vært-symbiont-associationer
EP2673344A4 (en) STABLE BIO OIL
CO6930368A2 (es) Composiciones de yodo-povidona estable
BR112013019150A2 (pt) engenharia do âmbito da imunoglobulina
CO6970600A2 (es) Derivados de betulina
DK2755481T3 (da) Anvendelse af alginatoligomerer til at forøge virkningerne af svampemidler
BR112013019287A2 (pt) composição inovadora de pesticidas
EP2552472A4 (en) INFLAMMATION INHIBITING FACTORS
DK3021839T3 (da) Sammensætninger for behandling af fibrose
CO6811866A2 (es) Derivados de benzamida sustituida
DK2800572T3 (da) Sammensætning af ellagitannin-rige ekstrakter
CO6791617A2 (es) Combinaciones de compuestos activos

Legal Events

Date Code Title Description
FC Application refused